Using artificial intelligence (AI) to help expedite processes for physicians can help them spend more face time with patients and stay up-to-date with the medical literature, says Douglas Flora, MD, FACCC.
Artificial intelligence (AI) has taken the country by storm in recent years, especially in the health care space. During the Association of Cancer Care Centers (ACCC) 51st Annual Meeting & Cancer Center Business Summit in Washington, DC, Douglas Flora, MD, FACCC, executive medical director of oncology services at St Elizabeth Healthcare, and editor in chief of AI in Precision Oncology, spoke about the challenges and opportunities posed by AI for oncology care providers.
In this interview, Flora explains how training AI to be used as a “personal assistant” for providers can help give them back more time to spend face-to-face with patients, also emphasizing the importance of protecting patient data.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
What specific challenges have you encountered in implementing AI solutions in oncology care, and what are some important factors to keep in mind for successful integration?
We’re early adopters, but everyone wants a little guidance. We've proceeded very cautiously around patient health information; we really want to make sure that's kept sacrosanct. It's our responsibility to our patients not to share their things, so a lot of the early discussions were governance, cybersecurity, make sure that PHI [protected health information] is protected. Those 18 things that we're not allowed to share with anyone else, a lot of the vendors wanted access to. We had to really work out, what are our rules, what are we most comfortable with, and once we established that, everything could proceed from there.
How do you envision the role of AI evolving in oncology over the next 5 years, and what steps do you think health care organizations should take now to prepare for these advancements?
I hope everybody's getting involved. I hope people are educating themselves. It is here. We will not put this back in Pandora's box.
I think it's a responsible approach for us—as leaders, as providers, as physicians—to learn this like we did immunology or genetics. We hadn't studied that since second year medical school, and we’re using it all day, every day now. So that's one.
Number 2, I would say, as we see these things evolve from just pattern recognizers and sort of data machines to things that really do think at the level of a human or even brighter than humans, I hope we use it for good. I don't want these systems to exist so I can see more patients a day. I want to be able to watch the daughter of my patient if she's getting hives because I've shared too much bad news, or watch the husband getting sort of sweaty and ashen because we can't deliver that much hard stuff in one visit, and I can't do that when I'm staring at my computer screen or looking down at my keyboard. That humanistic part of the approach for me is what I'm most excited about in the next 5 years.
Looking beyond that, I think every physician is going to need the help. It's going to be a personal assistant for each one of us to stay current in the medical literature, to know everything about our patient without having to collect it from 10 different sources, and then I can make better decisions for my patients. So, I'm excited to have the help.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More